Clinical Trial Update: Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

View source ↗

Summary

A completed clinical trial evaluated whether metabolomic analysis could guide adalimumab therapy in Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Adalimumab (Humira) (adalimumab)

Snippet

Sponsor: Martin Storr | Conditions: Crohn's Disease | Status: COMPLETED